MacroGenics, Inc. announced a partial clinical hold on its Phase 2 LINNET study of lorigerlimab for gynecologic cancers by the FDA due to recent safety events. The hold affects new patient enrollment, not current participants. Safety events included Grade 4 thrombocytopenia, myocarditis, and neutropenia with septic shock. 41 patients have been dosed in the study. The Company is prioritizing patient safety and working with the FDA to lift the hold. The LINNET study evaluates lorigerlimab as monotherapy for ovarian and gynecologic cancers. MacroGenics is focused on developing antibody-based therapeutics for cancer treatment.

Read more at GlobeNewswire: MacroGenics Announces Pausing of Enrollment of New Study